Hospital Universitario Central de Asturias -ko ikertzaileekin lankidetzan egindako argitalpenak (10)

2023

  1. Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients

    Medicina (Kaunas, Lithuania), Vol. 59, Núm. 8

2020

  1. Comparative study between two european inception cohorts of patients with early systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 38, Núm. 5, pp. 925-932

2018

  1. Combined mepacrine–hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity

    Lupus, Vol. 27, Núm. 10, pp. 1718-1722

  2. Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort

    Lupus, Vol. 27, Núm. 14, pp. 2253-2261

  3. Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study

    Arthritis Care and Research, Vol. 70, Núm. 4, pp. 582-591

2017

  1. Características clínicas al diagnóstico de una cohorte prospectiva de pacientes con lupus eritematoso sistémico atendidos en servicios de Medicina Interna españoles: estudio RELES

    Revista Clinica Espanola, Vol. 217, Núm. 1, pp. 7-14

2016

  1. First month prednisone dose predicts prednisone burden during the following 11 months: An observational study from the RELES cohort

    Lupus Science and Medicine, Vol. 3, Núm. 1

  2. Off-label use of rituximab for systemic lupus erythematosus in Europe

    Lupus Science and Medicine, Vol. 3, Núm. 1

  3. Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 34, Núm. 3, pp. 466-472

2010

  1. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases

    Clinical and Experimental Rheumatology, Vol. 28, Núm. 4, pp. 468-476